FAQ

Nexavar

 

Topic mentions per year

Topic mentions per year

2006-2018
05101520062018

Related topics

Related topics

2 relations

Broader (2)

sorafenibsorafenib tosylate

Related mentions per year

Related mentions per year

1974-2018
197019801990200020102020
Nexavar
sorafenib
sorafenib tosylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.
Prior tumor cell studies have shown that the drugs sorafenib (Nexavar) and regorafenib (Stivarga) reduce expression of the… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Pemetrexed (ALIMTA, Lilly) is a folate antimetabolite that has been approved by the U.S. Food and Drug Administration for the… (More)
Is this relevant?
2010
2010
The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
The majority of kinase inhibitors developed to date are competitive inhibitors that target the ATP binding site; however, recent… (More)
Is this relevant?
2010
2010
Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Signal transducers and activators of transcription 3 (STAT3) is constitutively active in human pancreatic cancer cells and can… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib
Chronic eosinophilic leukemia (CEL) is a rare myeloproliferative neoplasm characterized by the FIP1L1-PDGFRA fusion gene, variant… (More)
  • figure 1
  • figure 2
Is this relevant?
2008
2008
Recombinant human endostatin-associated acute left heart failure.
 
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
OBJECTIVE Sorafenib (Nexavar) is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis. This phase II study… (More)
  • table 2
  • table 1
  • figure 1
  • figure 2
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Antitumor activity of sorafenib in FLT3-driven leukemic cells
Activating internal tandem duplication (ITD) insertions in the juxtamembrane domain of the FLT3 tyrosine kinase are found in… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Angiogenesis and signaling through the RAF/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Activating mutations in Ras and B-RAF were identified in several human cancers. In addition, several receptor tyrosine kinases… (More)
Is this relevant?